Press releases

Press releases

01 August 2016  - Paris (France)

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older

28 July 2016  - Paris (France)

Ipsen's First Half 2016 Results

28 July 2016  - Tokyo (Japan), Paris (France)

Supplemental Application Filed for Somatuline® in Japan for Additional Indication of Neuroendocrine Tumors

22 July 2016  - Paris (France)

Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

18 July 2016  - Paris (France)

Ipsen announces the acceptance by the European Medicines Agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues

11 July 2016  - Paris (France)

David Meek appointed as Chief Executive Officer of Ipsen

09 June 2016  - Paris (France)

Ipsen successfully issues inaugural €300 million 7-year Notes

06 June 2016  - Paris (France)

The Ipsen Group launches an employee shareholding plan

06 June 2016  - Paris (France)

Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX™ (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

05 June 2016  - Paris (France)

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Updated on 11 July 2016